Patent Settlements DO Help Patients | Association for Accessible Medicines

Patent Settlements DO Help Patients

Wonder why the generic industry opposes a bill purported to help the generic industry?

Fact Check
Fact Check
In 2013, the Supreme Court prohibited “pay-for-delay” deals and the
Federal Trade Commission reviews all deals to ensure compliance.
Fact Check

Fact Check
The Federal Trade Commission reviews more than 140 agreements every year, and they found the vast majority do not delay generic competition. 
Fact Check

Fact Check
“Pay-for-delay” legislation turns back the clock and would make many patent settlements unlawful all the way back to 2013. This would deprive patients of generic drugs they count on now and delay access for future generics and biosimilars.
Fact Check

Fact Check
The vast majority of agreements (92 percent) accelerate patient access to more affordable medicine.
Fact Check

Fact Check
“Pay-for-delay” legislation will delay patient access to more affordable medicine and force patients to continue to pay the high price of brand-name drugs.
Fact Check

Fact Check
“Pay-for-delay” legislation could delay biosimilar competition on Humira — the top-selling drug in the U.S. — by 11 years, forcing patients to wait for more affordable alternatives until 2034.
Fact Check

Fact Check
AAM supports modifying "pay-for-delay" legislation to preserve the Supreme Court's Actavis decision and provide for substantial consumer cost-savings through timely generic entry.


Want to dive deeper? Download our full fact sheet on patent settlements:

Fact Sheet


Settlements Get Affordable Rx to Patients Faster.
Misguided Legislation Hurts Access. 

Additional Resources:

Issues

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.